首页> 外文期刊>Bulletin of pharmaceutical sciences >DEVELOPMENT AND CHARACTERIZATION OF NANO-STRUCTURED LIPID CARRIERS FOR TRANSDERMAL DELIVERY OF MELOXICAM
【24h】

DEVELOPMENT AND CHARACTERIZATION OF NANO-STRUCTURED LIPID CARRIERS FOR TRANSDERMAL DELIVERY OF MELOXICAM

机译:纳米结构脂质载体的透皮递送乳氧脲透皮携带者的开发与表征

获取原文
获取原文并翻译 | 示例
           

摘要

For transdermal delivery of meloxieam, nanostructured lipid carriers containing compriiol as solid lipid, oleic acid as liquid lipid and different ratios ofPlnronic F-68 were prepared. The prepared nanoparticles were characterized in terms of size, polydispersity index, zeta-potential and encapsulation efficiency. The average particle size, zeta-potential and encapsulation efficiency ranged from 134 to 491 nm, from -12.4 to -23.23 mV and from 35 to 70%, respectively. Furthermore, in vitro release for a number of selected formulations was performed using dialysis membrane in phosphate buffer saline. Drug release from free solution compared to release from nanostructured lipid carriers over a period of 48 hours was evaluated as well as release kinetic analysis was investigated. Moreover, stability of the selected formulation was studied at different time intervals. In addition, meloxicam-loaded nanostructured lipid carriers gel containing Carbopol-934 as a gelling agent was prepared. Moreover, anti-inflammatory activity of the prepared gel was evaluated using carrageenan-induced rat paw edema method, Meloxicam-loaded nanostructured lipid carriers gel showed a more sustained inhibitory effect compared to free meloxieam gel. Finally, toxicity of the prepared meloxicam-loaded nanostructured lipid carriers gel was evaluated using histopathological examination.
机译:为了经皮给药,制备了纳米结构的脂质载体,包括以康比醇为固体脂质、油酸为液体脂质和不同比例的聚乳酸F-68。对制备的纳米颗粒进行了粒径、多分散指数、zeta电位和包封率表征。平均粒径、zeta电位和包封效率分别为134-491nm、-12.4-23.23mv和35-70%。此外,在磷酸盐缓冲盐水中使用透析膜对许多选定配方进行体外释放。对48小时内从游离溶液中释放的药物与从纳米结构脂质载体中释放的药物进行了比较,并对释放动力学进行了研究。此外,还研究了所选配方在不同时间间隔下的稳定性。此外,制备了以卡波姆-934为胶凝剂的美洛昔康纳米结构脂质载体凝胶。此外,使用角叉菜胶诱导的大鼠足肿胀法评估所制备凝胶的抗炎活性,与游离美洛昔胺凝胶相比,负载美洛昔康的纳米结构脂质载体凝胶显示出更持久的抑制作用。最后,通过组织病理学检查评估制备的美洛昔康纳米结构脂质载体凝胶的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号